(Reuters) -Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company’s gene therapies has died from acute liver failure.
The latest death marks the third treatment-related fatality this year. Two teenage boys have died after receiving Sarepta’s Elevidys, a gene therapy approved to treat a rare muscular dystrophy.
Sarepta did not immediately respond to a Reuters request for comment outside of its business hours.
The patient was enrolled in a study testing Sarepta’s gene therapy to treat another muscle-wasting disorder called limb-girdle muscular dystrophy, according to the Bloomberg report, which cited a company spokesperson.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
Comments